NCT05785026Recruiting
Menthol for Dyspnea Relief in Health and COPD
Effectiveness and Mechanisms of Menthol Inhalation for the Relief of Dyspnea in Health and COPD
Source: ClinicalTrials.gov · Last updated 19 Nov 2025
Brief summary (registry, in English)
Menthol inhalation (MI) is a novel and promising treatment option for acute relief of dyspnea, however, the underlying ventilatory and/or neural related mechanisms for this relief in symptoms remain unknown. The overall aim of this research project is to systematically examine the mechanisms of dyspnea relief from MI in healthy individuals and those with COPD.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 7 Feb 2023
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Oct 2028
- Lead sponsor
- KU Leuven
- Diseases
- COPD
- NCT number
- NCT05785026
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 1 Jan 2023 to the primary completion date, 31 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindication to exercise testing (e.g., significant cardiovascular, musculoskeletal, neurological disease; see Table 4 from ERS/ATS consensus statement)
- Significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could influence dyspnea and/or impair exercise capacity (with the exception of COPD in WP3 and 4)
- An ulcer or tumor in the esophagus, a nasal septum deviation, or recent nasopharyngeal surgery
- Allergies to latex and sensitivities to local anesthetics
- Inability to give informed consent, including those with significant cognitive impairment
Age
- History of early menopause (age \<45 years)
Other
- Body mass index \<18.5 or \>35 kg/m2
- Severe facial trauma including cribriform plate disruption (bone separating brain from nasal cavity)
- Alcohol consumption within 12 hours of study visit
- Current smoker\*
- Pregnancy or desire to become pregnant while in trial
Who the study is looking for
- Age: 18 years of age or older
- Able to speak, read, and write Dutch or English
- Normal pulmonary function: forced expiratory volume in 1 second (FEV1) to forced vital capacity ratio\>0.70; FEV1≥80%predicted (WP1 and 2 only)
- Non-smoker or former smokers (smoke-free ≥12 months prior to enrolment) (WP1 and 2 only)
- Clinically stable COPD (based on clinical judgment of the study physician that have not had exacerbations requiring escalation of medical therapy (i.e., short course of oral corticosteroids or antibiotics) within the preceding 14 days (WP3 and 4 only)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.